Clinical efficacy and safety of nazartinib for epidermal growth factor receptor mutated non-small cell lung cancer: Study protocol for a prospective, multicenter, open-label.

Abstract excerpt

BACKGROUND: Nazartinib is considered a new, permanent, and mutant-selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). It has a demonstrated efficacy to treat patients experiencing EGFR-mutated non-small cell cancer (NSCLC). The present study aims to explore the clinical efficacy and safety of nazartinib in patients experiencing EGFR-mutated NSCLC. MATERIALS AND METHODS: The present...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Benzimidazoles
• Share to Carcinoma, Non-Small-Cell Lung